BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77-81. [PMID: 8531962 DOI: 10.1056/nejm199601113340203] [Cited by in Crossref: 732] [Cited by in F6Publishing: 202] [Article Influence: 29.3] [Reference Citation Analysis]
Number Citing Articles
1 Reed KE, Xu J, Rice CM. Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase. J Virol 1997;71:7187-97. [PMID: 9311791 DOI: 10.1128/JVI.71.10.7187-7197.1997] [Cited by in Crossref: 129] [Cited by in F6Publishing: 60] [Article Influence: 5.4] [Reference Citation Analysis]
2 Funaoka Y, Sakamoto N, Suda G, Itsui Y, Nakagawa M, Kakinuma S, Watanabe T, Mishima K, Ueyama M, Onozuka I, Nitta S, Kitazume A, Kiyohashi K, Murakawa M, Azuma S, Tsuchiya K, Watanabe M. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J Virol 2011;85:5986-94. [PMID: 21490101 DOI: 10.1128/JVI.02583-10] [Cited by in Crossref: 44] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
3 Fujita N, Nakanishi M, Mukai J, Naito Y, Ichida T, Kaito M, Yoshikawa T, Takei Y. Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis. Mol Med 2011;17:70-8. [PMID: 20927485 DOI: 10.2119/molmed.2010.00124] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Yatsuhashi H, Izumi N. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol 2011;46:401-9. [PMID: 20830599 DOI: 10.1007/s00535-010-0322-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
5 Nakagawa M, Sakamoto N, Ueyama M, Mogushi K, Nagaie S, Itsui Y, Azuma S, Kakinuma S, Tanaka H, Enomoto N, Watanabe M. Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. J Gastroenterol 2010;45:656-65. [DOI: 10.1007/s00535-009-0195-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
6 He Y, Tan SL, Tareen SU, Vijaysri S, Langland JO, Jacobs BL, Katze MG. Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A. J Virol. 2001;75:5090-5098. [PMID: 11333890 DOI: 10.1128/jvi.75.11.5090-5098.2001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
7 Masaki N, Fukushima S, Hayashi S. Lower th-1/th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C. Dig Dis Sci. 2002;47:2163-2169. [PMID: 12395887 DOI: 10.1023/a:1020114722763] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
8 Horner SM. Insights into antiviral innate immunity revealed by studying hepatitis C virus. Cytokine 2015;74:190-7. [PMID: 25819428 DOI: 10.1016/j.cyto.2015.03.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
9 Nakamoto S, Imazeki F, Arai M, Yasui S, Nakamura M, Haga Y, Sasaki R, Kanda T, Shirasawa H, Yokosuka O. Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy. Int J Mol Sci 2015;16:21177-90. [PMID: 26370958 DOI: 10.3390/ijms160921177] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World J Hepatol 2013; 5(9): 496-504 [PMID: 24073301 DOI: 10.4254/wjh.v5.i9.496] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
11 Yotsuyanagi H, Koike K. Drug resistance in antiviral treatment for infections with hepatitis B and C viruses. J Gastroenterol 2007;42:329-35. [PMID: 17530355 DOI: 10.1007/s00535-007-2034-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
12 Chung RT, He W, Saquib A, Contreras AM, Xavier RJ, Chawla A, Wang TC, Schmidt EV. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc Natl Acad Sci USA. 2001;98:9847-9852. [PMID: 11493707 DOI: 10.1073/pnas.171319698] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 2.6] [Reference Citation Analysis]
13 Zhou XM, Chan PK, Tam JS. Mutations around interferon sensitivity-determining region: A pilot resistance report of hepatitis C virus 1b in a Hong Kong population. World J Gastroenterol 2011; 17(48): 5317-5323 [PMID: 22219602 DOI: 10.3748/wjg.v17.i48.5317] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
14 Margeridon-Thermet S, Shafer RW. Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses. 2010;2:2696-2739. [PMID: 21243082 DOI: 10.3390/v2122696] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
15 Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014; 20(11): 2902-2912 [PMID: 24659881 DOI: 10.3748/wjg.v20.i11.2902] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 84] [Article Influence: 13.3] [Reference Citation Analysis]
16 Izumi N, Asahina Y, Kurosaki M. Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat 2010;2010:703602. [PMID: 21188200 DOI: 10.1155/2010/703602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
17 Chayama K, Hayes CN, Yoshioka K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. J Gastroenterol 2011;46:545-55. [PMID: 21246384 DOI: 10.1007/s00535-010-0358-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
18 Nousbaum J, Polyak SJ, Ray SC, Sullivan DG, Larson AM, Carithers RL, Gretch DR. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol. 2000;74:9028-9038. [PMID: 10982347 DOI: 10.1128/jvi.74.19.9028-9038.2000] [Cited by in Crossref: 87] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
19 Reed KE, Gorbalenya AE, Rice CM. The NS5A/NS5 proteins of viruses from three genera of the family flaviviridae are phosphorylated by associated serine/threonine kinases. J Virol 1998;72:6199-206. [PMID: 9621090 DOI: 10.1128/JVI.72.7.6199-6206.1998] [Cited by in Crossref: 98] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
20 Nakano I, Fukuda Y, Katano Y, Toyoda H, Hayashi K, Hayakawa T, Kumada T, Nakano S. Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype. Gut 2001;49:263-7. [PMID: 11454804 DOI: 10.1136/gut.49.2.263] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
21 Shiratori Y, Nakata R, Shimizu N, Katada H, Hisamitsu S, Yasuda E, Matsumura M, Narita T, Kawada K, Omata M. High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group. Dig Dis Sci. 2000;45:2414-2421. [PMID: 11258568 DOI: 10.1023/a:1005655428563] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
22 Ren Y, Wang W, Zhang X, Xu Y, Di Bisceglie AM, Fan X. Evidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy. J Gen Virol 2016;97:334-43. [PMID: 26581744 DOI: 10.1099/jgv.0.000346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 Jun CH, Ki HS, Lee HK, Park KJ, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. World J Gastroenterol 2013; 19(2): 284-289 [PMID: 23345952 DOI: 10.3748/wjg.v19.i2.284] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
24 Lara J, Khudyakov Y. Epistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance. Antivir Ther 2012;17:1471-5. [PMID: 23321567 DOI: 10.3851/IMP2478] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
25 Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA. 2002;99:3081-3086. [PMID: 11880647 DOI: 10.1073/pnas.052712599] [Cited by in Crossref: 144] [Cited by in F6Publishing: 148] [Article Influence: 7.6] [Reference Citation Analysis]
26 Gale M Jr, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998;18:5208-18. [PMID: 9710605 DOI: 10.1128/MCB.18.9.5208] [Cited by in Crossref: 437] [Cited by in F6Publishing: 188] [Article Influence: 19.0] [Reference Citation Analysis]
27 Ye J, Wang C, Sumpter R, Brown MS, Goldstein JL, Gale M. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA. 2003;100:15865-15870. [PMID: 14668447 DOI: 10.1073/pnas.2237238100] [Cited by in Crossref: 273] [Cited by in F6Publishing: 265] [Article Influence: 15.2] [Reference Citation Analysis]
28 Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol. 2001;75:4614-4624. [PMID: 11312331 DOI: 10.1128/jvi.75.10.4614-4624.2001] [Cited by in Crossref: 418] [Cited by in F6Publishing: 211] [Article Influence: 20.9] [Reference Citation Analysis]
29 Rispeter K, Lu M, Behrens SE, Fumiko C, Yoshida T, Roggendorf M. Hepatitis C virus variability: sequence analysis of an isolate after 10 years of chronic infection. Virus Genes. 2000;21:179-188. [PMID: 11129633 DOI: 10.1023/a:1008135413215] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
30 Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Wakabayashi H, Ohkoshi S, Tsukishiro T, Takahashi T, Watanabe T, Terai S. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C. World J Hepatol 2017; 9(5): 252-262 [PMID: 28261382 DOI: 10.4254/wjh.v9.i5.252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Jassey A, Liu CH, Changou CA, Richardson CD, Hsu HY, Lin LT. Hepatitis C Virus Non-Structural Protein 5A (NS5A) Disrupts Mitochondrial Dynamics and Induces Mitophagy. Cells 2019;8:E290. [PMID: 30934919 DOI: 10.3390/cells8040290] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
32 Enomoto H, Nishiguchi S. Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C. World J Hepatol 2015; 7(26): 2681-2687 [PMID: 26609345 DOI: 10.4254/wjh.v7.i26.2681] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
33 Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, Shindo H, Ohmori T, Kanayama A, Shindo K, Amemiya F. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. Hepatol Int. 2012;6:386-396. [PMID: 22020823 DOI: 10.1007/s12072-011-9307-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
34 Sklan EH, Charuworn P, Pang PS, Glenn JS. Mechanisms of HCV survival in the host. Nat Rev Gastroenterol Hepatol. 2009;6:217-227. [PMID: 19347013 DOI: 10.1038/nrgastro.2009.32] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
35 Serre SB, Krarup HB, Bukh J, Gottwein JM. Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance. J Virol 2013;87:12776-93. [PMID: 24049176 DOI: 10.1128/JVI.00901-13] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
36 El Awady MK, Bader El Din NG, Tabll A, El Hosary Y, Abdel Aziz AO, El Khayat H, Salama M, Abdelhafez TH. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients. World J Gastroenterol 2013; 19(2): 290-298 [PMID: 23345953 DOI: 10.3748/wjg.v19.i2.290] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
37 Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load. J Gastroenterol. 2012;47:1143-1151. [PMID: 22441534 DOI: 10.1007/s00535-012-0578-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
38 Banerjee A, Ray RB, Ray R. Oncogenic potential of hepatitis C virus proteins. Viruses. 2010;2:2108-2133. [PMID: 21994721 DOI: 10.3390/v2092108] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 6.9] [Reference Citation Analysis]
39 Sandres K, Dubois M, Pasquier C, Payen JL, Alric L, Duffaut M, Vinel JP, Pascal JP, Puel J, Izopet J. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol 2000;74:661-8. [PMID: 10623727 DOI: 10.1128/jvi.74.2.661-668.2000] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
40 Wei S, Hu X, Du L, Zhao L, Xue H, Liu C, Chou JJ, Zhong J, Tong Y, Wang S, OuYang B. Inhibitor Development against p7 Channel in Hepatitis C Virus. Molecules 2021;26:1350. [PMID: 33802584 DOI: 10.3390/molecules26051350] [Reference Citation Analysis]
41 Yang C, Zhao X, Sun D, Yang L, Chong C, Pan Y, Chi X, Gao Y, Wang M, Shi X. Interferon alpha (IFNα)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A. Cell Mol Immunol. 2015;Epub ahead of print. [PMID: 25683609 DOI: 10.1038/cmi.2014.131] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 9.5] [Reference Citation Analysis]
42 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Reference Citation Analysis]
43 Patra T, Ray RB, Ray R. Strategies to Circumvent Host Innate Immune Response by Hepatitis C Virus. Cells 2019;8:E274. [PMID: 30909456 DOI: 10.3390/cells8030274] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
44 Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection. J Clin Microbiol 2014;52:193-200. [PMID: 24197875 DOI: 10.1128/JCM.02371-13] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
45 Rubbo PA, Van de Perre P, Tuaillon E. The long way toward understanding host and viral determinants of therapeutic success in HCV infection. Hepatol Int 2012;6:436-40. [PMID: 26201406 DOI: 10.1007/s12072-011-9339-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Dusheiko GM, Khakoo S, Soni P, Grellier L. A rational approach to the management of hepatitis C infection. BMJ 1996;312:357-64. [PMID: 8611836 DOI: 10.1136/bmj.312.7027.357] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
47 Lim SP, Khu YL, Hong WJ, Tay A, Ting AE, Lim SG, Tan YH. Identification and molecular characterisation of the complete genome of a Singapore isolate of hepatitis C virus: sequence comparison with other strains and phylogenetic analysis. Virus Genes 2001;23:89-95. [PMID: 11556407 DOI: 10.1023/a:1011143731677] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
48 Zhang Q, Gong R, Qu J, Zhou Y, Liu W, Chen M, Liu Y, Zhu Y, Wu J. Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway. J Virol. 2012;86:1544-1554. [PMID: 22114332 DOI: 10.1128/jvi.00688-11] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
49 Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. J Virol 1998;72:2795-805. [PMID: 9525599 DOI: 10.1128/JVI.72.4.2795-2805.1998] [Cited by in Crossref: 148] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
50 Maekawa S, Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol. 2009;44:1009-1015. [PMID: 19756352 DOI: 10.1007/s00535-009-0126-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
51 Martell M, Briones C, de Vicente A, Piron M, Esteban JI, Esteban R, Guardia J, Gómez J. Structural analysis of hepatitis C RNA genome using DNA microarrays. Nucleic Acids Res 2004;32:e90. [PMID: 15247323 DOI: 10.1093/nar/gnh088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
52 Moreno MP, Casane D, López L, Cristina J. Evidence of recombination in quasispecies populations of a Hepatitis C Virus patient undergoing anti-viral therapy. Virol J. 2006;3:87. [PMID: 17062150 DOI: 10.1186/1743-422x-3-87] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
53 Arumugaswami V, Remenyi R, Kanagavel V, Sue EY, Ngoc Ho T, Liu C, Fontanes V, Dasgupta A, Sun R. High-resolution functional profiling of hepatitis C virus genome. PLoS Pathog 2008;4:e1000182. [PMID: 18927624 DOI: 10.1371/journal.ppat.1000182] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
54 Polyak SJ, Khabar KS, Paschal DM, Ezelle HJ, Duverlie G, Barber GN, Levy DE, Mukaida N, Gretch DR. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol. 2001;75:6095-6106. [PMID: 11390611 DOI: 10.1128/jvi.75.13.6095-6106.2001] [Cited by in Crossref: 218] [Cited by in F6Publishing: 84] [Article Influence: 10.9] [Reference Citation Analysis]
55 Lemon SM. Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem 2010;285:22741-7. [PMID: 20457596 DOI: 10.1074/jbc.R109.099556] [Cited by in Crossref: 83] [Cited by in F6Publishing: 58] [Article Influence: 7.5] [Reference Citation Analysis]
56 Geiss GK, Carter VS, He Y, Kwieciszewski BK, Holzman T, Korth MJ, Lazaro CA, Fausto N, Bumgarner RE, Katze MG. Gene expression profiling of the cellular transcriptional network regulated by alpha/beta interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein. J Virol 2003;77:6367-75. [PMID: 12743294 DOI: 10.1128/jvi.77.11.6367-6375.2003] [Cited by in Crossref: 82] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
57 Ansari MA, Pedergnana V, L C Ip C, Magri A, Von Delft A, Bonsall D, Chaturvedi N, Bartha I, Smith D, Nicholson G, McVean G, Trebes A, Piazza P, Fellay J, Cooke G, Foster GR, Hudson E, McLauchlan J, Simmonds P, Bowden R, Klenerman P, Barnes E, Spencer CCA; STOP-HCV Consortium. Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nat Genet 2017;49:666-73. [PMID: 28394351 DOI: 10.1038/ng.3835] [Cited by in Crossref: 79] [Cited by in F6Publishing: 60] [Article Influence: 19.8] [Reference Citation Analysis]
58 Pang PS, Planet PJ, Glenn JS. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS One. 2009;4:e6579. [PMID: 19668364 DOI: 10.1371/journal.pone.0006579] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
59 Peng L, Liang D, Tong W, Li J, Yuan Z. Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J Biol Chem. 2010;285:20870-20881. [PMID: 20439463 DOI: 10.1074/jbc.m110.112045] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
60 Sallie R. Replicative homeostasis: a fundamental mechanism mediating selective viral replication and escape mutation. Virol J 2005;2:10. [PMID: 15707489 DOI: 10.1186/1743-422X-2-10] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
61 Mansoor A, Ali L, Sabah NU, Hashmi AH, Khan MH, Kazmi SA, Ahmad N, Siddiqi S, Khan KM. Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population. Virol J. 2013;10:352. [PMID: 24321105 DOI: 10.1186/1743-422x-10-352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Aizawa N, Enomoto H, Takashima T, Sakai Y, Iwata K, Ikeda N, Tanaka H, Iwata Y, Saito M, Imanishi H. Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2014;49:1253-1263. [PMID: 24065124 DOI: 10.1007/s00535-013-0884-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
63 Fimia GM, Evangelisti C, Alonzi T, Romani M, Fratini F, Paonessa G, Ippolito G, Tripodi M, Piacentini M. Conventional protein kinase C inhibition prevents alpha interferon-mediated hepatitis C virus replicon clearance by impairing STAT activation. J Virol. 2004;78:12809-12816. [PMID: 15542633 DOI: 10.1128/jvi.78.23.12809-12816.2004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
64 Kato N, Sejima H, Ueda Y, Mori K, Satoh S, Dansako H, Ikeda M. Genetic characterization of hepatitis C virus in long-term RNA replication using Li23 cell culture systems. PLoS One 2014;9:e91156. [PMID: 24625789 DOI: 10.1371/journal.pone.0091156] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
65 Kuntzen T, Berical A, Ndjomou J, Bennett P, Schneidewind A, Lennon N, Birren BW, Kuiken C, Henn MR, Simmonds P, Allen TM. A set of reference sequences for the hepatitis C genotypes 4d, 4f, and 4k covering the full open reading frame. J Med Virol 2008;80:1370-8. [PMID: 18551618 DOI: 10.1002/jmv.21240] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
66 Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol 2013; 19(47): 8940-8948 [PMID: 24379619 DOI: 10.3748/wjg.v19.i47.8940] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
67 Li H, Hughes AL, Bano N, McArdle S, Livingston S, Deubner H, McMahon BJ, Townshend-Bulson L, McMahan R, Rosen HR, Gretch DR. Genetic diversity of near genome-wide hepatitis C virus sequences during chronic infection: evidence for protein structural conservation over time. PLoS One 2011;6:e19562. [PMID: 21573177 DOI: 10.1371/journal.pone.0019562] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
68 Muñoz de Rueda P, Casado J, Patón R, Quintero D, Palacios A, Gila A, Quiles R, León J, Ruiz-Extremera A, Salmerón J. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol 2008;82:6644-53. [PMID: 18448540 DOI: 10.1128/JVI.02231-07] [Cited by in Crossref: 48] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
69 Guo JT, Zhu Q, Seeger C. Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons. J Virol 2003;77:10769-79. [PMID: 14512527 DOI: 10.1128/jvi.77.20.10769-10779.2003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
70 He Y, Nakao H, Tan SL, Polyak SJ, Neddermann P, Vijaysri S, Jacobs BL, Katze MG. Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J Virol 2002;76:9207-17. [PMID: 12186904 DOI: 10.1128/jvi.76.18.9207-9217.2002] [Cited by in Crossref: 131] [Cited by in F6Publishing: 54] [Article Influence: 6.9] [Reference Citation Analysis]
71 Yuan H, Adams-Huet B, Petersen T, Attar N, Lee WM, Jain MK. A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy. J Med Virol. 2012;84:1913-1919. [PMID: 23080496 DOI: 10.1002/jmv.23407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
72 Yildiz E, Oztan A, Sar F, Pinarbasi E, Cetin-Atalay R, Akkiz H, Ozturk M. Molecular characterization of a full genome Turkish hepatitis C virus 1b isolate (HCV-TR1): a predominant viral form in Turkey. Virus Genes 2002;25:169-77. [PMID: 12416679 DOI: 10.1023/a:1020161818764] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
73 Holysz M, Bialas K, Migdalski P, Kmieciak D, Trzeciak WH. Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy. J Appl Genet 2015;56:403-9. [PMID: 25588648 DOI: 10.1007/s13353-014-0267-0] [Reference Citation Analysis]
74 Saito H, Ebinuma H, Ojiro K, Wakabayashi K, Inoue M, Tada S, Hibi T. On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula. World J Gastroenterol 2010; 16(1): 89-97 [PMID: 20039454 DOI: 10.3748/wjg.v16.i1.89] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Weber F. Interaction of hepatitis C virus with the type I interferon system. World J Gastroenterol 2007; 13(36): 4818-4823 [PMID: 17828812 DOI: 10.3748/wjg.v13.i36.4818] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
76 Pickett BE, Striker R, Lefkowitz EJ. Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat 2011;18:608-18. [PMID: 20565573 DOI: 10.1111/j.1365-2893.2010.01342.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
77 Bittar C, Jardim AC, Yamasaki LH, de Queiróz AT, Carareto CM, Pinho JR, de Carvalho-Mello IM, Rahal P. Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response. BMC Infect Dis 2010;10:36. [PMID: 20178583 DOI: 10.1186/1471-2334-10-36] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
78 Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, Inoue T, Sakamoto M, Okada S, Asahina Y, Izumi N, Honda M, Kaneko S, Enomoto N. Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. Hepatol Int 2012;6:482-90. [PMID: 22020822 DOI: 10.1007/s12072-011-9306-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
79 Tamai H, Ida Y, Kawashima A, Shingaki N, Shimizu R, Moribata K, Nasu T, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M. Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus. Gut Liver 2017;11:551-8. [PMID: 28506030 DOI: 10.5009/gnl16525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Scheel TK, Prentoe J, Carlsen TH, Mikkelsen LS, Gottwein JM, Bukh J. Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems. PLoS Pathog 2012;8:e1002696. [PMID: 22654662 DOI: 10.1371/journal.ppat.1002696] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
81 Lam AM, Keeney D, Eckert PQ, Frick DN. Hepatitis C virus NS3 ATPases/helicases from different genotypes exhibit variations in enzymatic properties. J Virol 2003;77:3950-61. [PMID: 12634355 DOI: 10.1128/jvi.77.7.3950-3961.2003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
82 Mochizuki K, Kagawa T, Takashimizu S, Kawazoe K, Kojima SI, Nagata N, Nakano A, Nishizaki Y, Shiraishi K, Itakura M, Watanabe N, Mine T, Matsuzaki S. Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C. World J Gastroenterol 2004; 10(5): 733-736 [PMID: 14991949 DOI: 10.3748/wjg.v10.i5.733] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
83 Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009;44:952-963. [PMID: 19517057 DOI: 10.1007/s00535-009-0087-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 5.1] [Reference Citation Analysis]
84 Nagao Y, Sata M. A retrospective case-control study of hepatitis C virus infection and oral lichen planus in Japan: association study with mutations in the core and NS5A region of hepatitis C virus. BMC Gastroenterol 2012;12:31. [PMID: 22490000 DOI: 10.1186/1471-230X-12-31] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
85 Simmonds P. Clinical relevance of hepatitis C virus genotypes. Gut 1997;40:291-3. [PMID: 9135513 DOI: 10.1136/gut.40.3.291] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
86 Ishii K, Shinohara M, Kogame M, Shiratori M, Higami K, Kanayama K, Shiozawa K, Wakui N, Nagai H, Watanabe M, Sumino Y. Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4(+) T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load. Hepatol Int 2012;6:468-74. [PMID: 21818686 DOI: 10.1007/s12072-011-9305-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
87 Veillon P, Payan C, Le Guillou-Guillemette H, Gaudy C, Lunel F. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy. World J Gastroenterol 2007; 13(8): 1195-1203 [PMID: 17451199 DOI: 10.3748/wjg.v13.i8.1195] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
88 Tsukiyama-Kohara K, Kohara M. Hepatitis C Virus: Viral Quasispecies and Genotypes. Int J Mol Sci 2017;19:E23. [PMID: 29271914 DOI: 10.3390/ijms19010023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
89 Elazar M, Cheong KH, Liu P, Greenberg HB, Rice CM, Glenn JS. Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication. J Virol 2003;77:6055-61. [PMID: 12719597 DOI: 10.1128/jvi.77.10.6055-6061.2003] [Cited by in Crossref: 132] [Cited by in F6Publishing: 70] [Article Influence: 7.3] [Reference Citation Analysis]
90 Cuevas JM, Torres-Puente M, Jiménez-Hernández N, Bracho MA, García-Robles I, Wrobel B, Carnicer F, del Olmo J, Ortega E, Moya A, González-Candelas F. Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin. PLoS One 2008;3:e3058. [PMID: 18725975 DOI: 10.1371/journal.pone.0003058] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
91 Jain MK, Yuan HJ, Adams-Huet B, Reeck A, Shelton J, Attar N, Zhang S, Neumann AU, Carney DS, Gale M Jr, Lee WM. Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment. J Infect Dis 2009;200:866-76. [PMID: 19673650 DOI: 10.1086/605475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
92 Tu YC, Yu CY, Liang JJ, Lin E, Liao CL, Lin YL. Blocking double-stranded RNA-activated protein kinase PKR by Japanese encephalitis virus nonstructural protein 2A. J Virol 2012;86:10347-58. [PMID: 22787234 DOI: 10.1128/JVI.00525-12] [Cited by in F6Publishing: 46] [Reference Citation Analysis]
93 Asada A, Shioya M, Osaki R, Nishimura T, Takeuchi T, Okumura Y, Andoh A. MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection. Biomed Rep 2015;3:247-53. [PMID: 26075078 DOI: 10.3892/br.2014.406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
94 Ali I, Khan S, Attaullah S, Khan SN, Khan J, Siraj S, Iqbal A, Swati ZA, Idrees M. Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein. Virol J 2011;8:258. [PMID: 21609495 DOI: 10.1186/1743-422X-8-258] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
95 El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L, El-Raziky M, Jiang DP, Esmat G, Hotta H. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol. 2012;50:3886-3892. [PMID: 22993188 DOI: 10.1128/jcm.02109-12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
96 Mori KI, Matsumoto A, Maki N, Ichikawa Y, Tanaka E, Yagi S. Production of infectious HCV genotype 1b virus in cell culture using a novel Set of adaptive mutations. BMC Microbiol 2016;16:224. [PMID: 27678340 DOI: 10.1186/s12866-016-0846-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
97 Ninomiya M, Ueno Y, Funayama R, Nagashima T, Nishida Y, Kondo Y, Inoue J, Kakazu E, Kimura O, Nakayama K. Use of illumina deep sequencing technology to differentiate hepatitis C virus variants. J Clin Microbiol. 2012;50:857-866. [PMID: 22205816 DOI: 10.1128/jcm.05715-11] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
98 Ukai K, Ishigami M, Yoshioka K, Kawabe N, Katano Y, Hayashi K, Honda T, Yano M, Goto H. Mutations in carboxy-terminal part of E2 including PKR/eIF2α phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: Their correlation with response to interferon monotherapy and viral load. World J Gastroenterol 2006; 12(23): 3722-3728 [PMID: 16773689 DOI: 10.3748/wjg.v12.i23.3722] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
99 Ueda Y, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Miyagawa-Hayashino A, Haga H, Marusawa H, Teramukai S, Uemoto S, Chiba T. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation. PLoS One 2013;8:e58380. [PMID: 23505497 DOI: 10.1371/journal.pone.0058380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
100 Fujii H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Nakamura H, Yasui K, Minami M, Tanaka S, Ishikawa H, Kimura H, Takami S, Nagao Y, Shima T, Itoh Y. Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. World J Hepatol 2017; 9(25): 1064-1072 [PMID: 28951778 DOI: 10.4254/wjh.v9.i25.1064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
101 Schenk C, Meyrath M, Warnken U, Schnölzer M, Mier W, Harak C, Lohmann V. Characterization of a Threonine-Rich Cluster in Hepatitis C Virus Nonstructural Protein 5A and Its Contribution to Hyperphosphorylation. J Virol 2018;92:e00737-18. [PMID: 30258001 DOI: 10.1128/JVI.00737-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
102 Chen R, Kobewka M, Addison W, Lachance G, Tyrrell DL. Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice. PLoS One 2016;11:e0147007. [PMID: 26765841 DOI: 10.1371/journal.pone.0147007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
103 Bhattacharya D, Accola MA, Ansari IH, Striker R, Rehrauer WM. Naturally occurring genotype 2b/1a hepatitis C virus in the United States. Virol J. 2011;8:458. [PMID: 21967740 DOI: 10.1186/1743-422x-8-458] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
104 Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, Higuchi K, Okazaki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M. Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study. J Gastroenterol 2014;49:492-501. [PMID: 23543311 DOI: 10.1007/s00535-013-0785-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
105 Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs. 2002;62:507-556. [PMID: 11827565 DOI: 10.2165/00003495-200262030-00009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
106 Nagayama K, Enomoto N, Izumi N, Kurosaki M, Miyasaka Y, Watanabe H, Itakura J, Chen CH, Tazawa J, Hoshino Y, Ikeda T, Marumo F, Sato C. Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients. Gut 2001;48:830-5. [PMID: 11358904 DOI: 10.1136/gut.48.6.830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
107 Bukh J, Pietschmann T, Lohmann V, Krieger N, Faulk K, Engle RE, Govindarajan S, Shapiro M, St Claire M, Bartenschlager R. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci U S A. 2002;99:14416-14421. [PMID: 12391335 DOI: 10.1073/pnas.212532699.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
108 Rivas-Estilla AM, Svitkin Y, Lopez Lastra M, Hatzoglou M, Sherker A, Koromilas AE. PKR-dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone. J Virol. 2002;76:10637-10653. [PMID: 12368306 DOI: 10.1128/jvi.76.21.10637-10653.2002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
109 Coito C, Diamond DL, Neddermann P, Korth MJ, Katze MG. High-throughput screening of the yeast kinome: identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein. J Virol. 2004;78:3502-3513. [PMID: 15016873 DOI: 10.1128/jvi.78.7.3502-3513.2004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
110 Harada N, Tamura S, Sugawara Y, Togashi J, Ishizawa T, Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, Tanaka T, Yamashiki N, Kokudo N. Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C. PLoS One 2014;9:e90462. [PMID: 24599320 DOI: 10.1371/journal.pone.0090462] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
111 Chung KM, Lee J, Kim JE, Song OK, Cho S, Lim J, Seedorf M, Hahm B, Jang SK. Nonstructural protein 5A of hepatitis C virus inhibits the function of karyopherin beta3. J Virol 2000;74:5233-41. [PMID: 10799599 DOI: 10.1128/jvi.74.11.5233-5241.2000] [Cited by in Crossref: 55] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
112 Watanabe T, Imamura T, Hiasa Y. Roles of protein kinase R in cancer: Potential as a therapeutic target. Cancer Sci 2018;109:919-25. [PMID: 29478262 DOI: 10.1111/cas.13551] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
113 van Tol S, Hage A, Giraldo MI, Bharaj P, Rajsbaum R. The TRIMendous Role of TRIMs in Virus-Host Interactions. Vaccines (Basel) 2017;5:E23. [PMID: 28829373 DOI: 10.3390/vaccines5030023] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 12.8] [Reference Citation Analysis]
114 Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. World J Hepatol 2015; 7(28): 2841-2848 [PMID: 26668696 DOI: 10.4254/wjh.v7.i28.2841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
115 Gale M Jr, Tan SL, Katze MG. Translational control of viral gene expression in eukaryotes. Microbiol Mol Biol Rev 2000;64:239-80. [PMID: 10839817 DOI: 10.1128/MMBR.64.2.239-280.2000] [Cited by in Crossref: 235] [Cited by in F6Publishing: 142] [Article Influence: 11.2] [Reference Citation Analysis]
116 Ogata S, Florese RH, Nagano-Fujii M, Hidajat R, Deng L, Ku Y, Yoon S, Saito T, Kawata S, Hotta H. Identification of hepatitis C virus (HCV) subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the HCV NS3 protein. J Clin Microbiol 2003;41:2835-41. [PMID: 12843009 DOI: 10.1128/JCM.41.7.2835-2841.2003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
117 François C, Duverlie G, Rebouillat D, Khorsi H, Castelain S, Blum HE, Gatignol A, Wychowski C, Moradpour D, Meurs EF. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J Virol. 2000;74:5587-5596. [PMID: 10823866 DOI: 10.1128/jvi.74.12.5587-5596.2000] [Cited by in Crossref: 96] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
118 Hazari S, Taylor L, Haque S, Garry RF, Florman S, Luftig R, Regenstein F, Dash S. Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Virol J 2007;4:89. [PMID: 17877826 DOI: 10.1186/1743-422X-4-89] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
119 Wada Y, Tamai H, Kawashima A, Shingaki N, Mori Y, Kawaguchi M, Moribata K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C. Gut Liver 2014;8:421-7. [PMID: 25071908 DOI: 10.5009/gnl.2014.8.4.421] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
120 Lee SM, Schommer SK, Kleiboeker SB. Porcine reproductive and respiratory syndrome virus field isolates differ in in vitro interferon phenotypes. Vet Immunol Immunopathol 2004;102:217-31. [PMID: 15507307 DOI: 10.1016/j.vetimm.2004.09.009] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 4.6] [Reference Citation Analysis]
121 Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamuta M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, Yoneda M, Murata K, Ito K, Koike K, Mizokami M. Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C. J Gastroenterol Hepatol 2014;29:1996-2005. [PMID: 24910341 DOI: 10.1111/jgh.12646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
122 Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, Lunel-Fabiani F. Genetic diversity of the hepatitis C virus: Impact and issues in the antiviral therapy. World J Gastroenterol 2007; 13(17): 2416-2426 [PMID: 17552024 DOI: 10.3748/wjg.v13.i17.2416] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 56] [Article Influence: 4.3] [Reference Citation Analysis]
123 Uto H, Mawatari S, Kumagai K, Ido A, Tsubouchi H. Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels. Hepat Mon 2012;12:77-84. [PMID: 22509183 DOI: 10.5812/hepatmon.829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
124 Shiratori Y, Kato N, Yoshida H, Nakata R, Ihori M, Imazeki F, Yokosuka O, Kawase T, Katamoto T, Unuma T, Nakamura A, Ikegami F, Hirota K, Omata M. Sustained viral response is rarely achieved in patients with high viral load of HCV RNA by excessive interferon therapy. Dig Dis Sci 2000;45:565-74. [PMID: 10749334 DOI: 10.1023/a:1005457510354] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
125 Izumi N, Kumada H, Hashimoto N, Harada H, Imawari M, Zeniya M, Toda G. Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study. Dig Dis Sci 2001;46:516-23. [PMID: 11318525 DOI: 10.1023/a:1005686829416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
126 Miyake T, Hiasa Y, Hirooka M, Tokumoto Y, Watanabe T, Furukawa S, Ueda T, Yamamoto S, Kumagi T, Miyaoka H, Abe M, Matsuura B, Onji M. High serum palmitic acid is associated with low antiviral effects of interferon-based therapy for hepatitis C virus. Lipids 2012;47:1053-62. [PMID: 22983804 DOI: 10.1007/s11745-012-3716-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
127 Lapa D, Garbuglia AR, Capobianchi MR, Del Porto P. Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay? Cells 2019;8:E305. [PMID: 30987134 DOI: 10.3390/cells8040305] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
128 Laufer N, Bolcic F, Rolón MJ, Martinez A, Reynoso R, Pérez H, Salomón H, Cahn P, Quarleri J. HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin. Antiviral Res 2011;90:92-7. [PMID: 21376083 DOI: 10.1016/j.antiviral.2011.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
129 Plauzolles A, Lucas M, Gaudieri S. Influence of host resistance on viral adaptation: hepatitis C virus as a case study. Infect Drug Resist 2015;8:63-74. [PMID: 25897250 DOI: 10.2147/IDR.S49891] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
130 Sato M, Maekawa S, Komatsu N, Tatsumi A, Miura M, Muraoka M, Suzuki Y, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Uetake T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. J Virol. 2015;89:6105-6116. [PMID: 25810555 DOI: 10.1128/jvi.03127-14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
131 Schweitzer CJ, Liang TJ. Impact of host and virus genome variability on HCV replication and response to interferon. Curr Opin Virol 2013;3:501-7. [PMID: 23835049 DOI: 10.1016/j.coviro.2013.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
132 Muñoz de Rueda P, Fuentes Rodríguez JM, Quiles Pérez R, Gila Medina A, Martín Álvarez AB, Casado Ruíz J, Ruíz Extremera A, Salmerón J. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment. World J Gastroenterol 2017; 23(25): 4538-4547 [PMID: 28740342 DOI: 10.3748/wjg.v23.i25.4538] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
133 Takagi H, Takehara K, Shimoda R, Kakizaki S, Takayama H, Abe T, Yamada T, Hashimoto Y, Saitoh S, Matsumoto T, Kojima A, Takezawa J, Yuasa K, Moriguchi M, Sekiguchi T, Nagamine T, Mori M. Prediction of effect of interferon on chronic hepatitis C. Dig Dis Sci 1997;42:2270-6. [PMID: 9398805 DOI: 10.1023/a:1018866717753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
134 Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB, Dibisceglie AM. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol. 2005;79:3071-3083. [PMID: 15709027 DOI: 10.1128/jvi.79.5.3071-3083.2005] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
135 Omata M, Kanda T, Yu M, Yokosuka O, Lim S, Jafri W, Tateishi R, Hamid SS, Chuang W, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J, Mccaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35. [DOI: 10.1007/s12072-012-9342-y] [Cited by in Crossref: 114] [Cited by in F6Publishing: 128] [Article Influence: 12.7] [Reference Citation Analysis]
136 Yuan HJ, Lee WM. Nonresponse to treatment for hepatitis C: current management strategies. Drugs 2008;68:27-42. [PMID: 18081371 DOI: 10.2165/00003495-200868010-00003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
137 Lara J, Xia G, Purdy M, Khudyakov Y. Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy. J Virol 2011;85:3649-63. [PMID: 21248044 DOI: 10.1128/JVI.02197-10] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
138 Pfeiffer JK, Kirkegaard K. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol. 2005;79:2346-2355. [PMID: 15681435 DOI: 10.1128/jvi.79.4.2346-2355.2005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
139 Polyak SJ, McArdle S, Liu SL, Sullivan DG, Chung M, Hofgärtner WT, Carithers RL Jr, McMahon BJ, Mullins JI, Corey L, Gretch DR. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 1998;72:4288-96. [PMID: 9557719 DOI: 10.1128/JVI.72.5.4288-4296.1998] [Cited by in Crossref: 107] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
140 Dabo S, Meurs EF. dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses 2012;4:2598-635. [PMID: 23202496 DOI: 10.3390/v4112598] [Cited by in Crossref: 112] [Cited by in F6Publishing: 105] [Article Influence: 12.4] [Reference Citation Analysis]
141 Yoon J, Lee JI, Baik SK, Lee KH, Sohn JH, Lee HW, Namkung J, Chang SJ, Choi JW, Kim HW, Yeh BI. Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol 2007; 13(46): 6236-6242 [PMID: 18069766 DOI: 10.3748/wjg.v13.i46.6236] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
142 Sallie R. Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response. Virol J 2007;4:29. [PMID: 17355620 DOI: 10.1186/1743-422X-4-29] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
143 Pflugheber J, Fredericksen B, Sumpter R, Wang C, Ware F, Sodora DL, Gale M. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci U S A. 2002;99:4650-4655. [PMID: 11904369 DOI: 10.1073/pnas.062055699] [Cited by in Crossref: 129] [Cited by in F6Publishing: 124] [Article Influence: 6.8] [Reference Citation Analysis]
144 Jiang X, Kanda T, Wu S, Nakamoto S, Nakamura M, Sasaki R, Haga Y, Wakita T, Shirasawa H, Yokosuka O. Hepatitis C Virus Nonstructural Protein 5A Inhibits MG132-Induced Apoptosis of Hepatocytes in Line with NF-κB-Nuclear Translocation. PLoS One 2015;10:e0131973. [PMID: 26133378 DOI: 10.1371/journal.pone.0131973] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
145 Qi H, Chu V, Wu NC, Chen Z, Truong S, Brar G, Su SY, Du Y, Arumugaswami V, Olson CA, Chen SH, Lin CY, Wu TT, Sun R. Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein. Proc Natl Acad Sci U S A 2017;114:2018-23. [PMID: 28159892 DOI: 10.1073/pnas.1614623114] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
146 Alscher DM, Bode JC. [Therapy of hepatitis C]. Med Klin (Munich) 1997;92:147-61. [PMID: 9173207 DOI: 10.1007/BF03043273] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
147 Samokhvalov EI, Hijikata M, Gylka RI, Lvov DK, Mishiro S. Full-genome nucleotide sequence of a hepatitis C virus variant (isolate name VAT96) representing a new subtype within the genotype 2 (arbitrarily 2k). Virus Genes 2000;20:183-7. [PMID: 10872881 DOI: 10.1023/a:1008182901274] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
148 Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, Izumi N. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. BMC Infect Dis 2012;12:324. [PMID: 23181537 DOI: 10.1186/1471-2334-12-324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
149 Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol. 2002;76:11079-11090. [PMID: 12368350 DOI: 10.1128/jvi.76.21.11079-11090.2002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
150 Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M. Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. PLoS One. 2011;6:e24514. [PMID: 21935415 DOI: 10.1371/journal.pone.0024514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
151 Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M. Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy. Hepatol Int. 2011;5:789-799. [PMID: 21484117 DOI: 10.1007/s12072-011-9267-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
152 Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H. Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients. Gastroenterol Res Pract. 2014;2014:549709. [PMID: 25197269 DOI: 10.1155/2014/549709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
153 Fuchizaki U, Kaneko S, Nakamoto Y, Sugiyama Y, Imagawa K, Kikuchi M, Kobayashi K. Synergistic antiviral effect of a combination of mouse interferon-alpha and interferon-gamma on mouse hepatitis virus. J Med Virol 2003;69:188-94. [PMID: 12683406 DOI: 10.1002/jmv.10286] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
154 Kumthip K, Maneekarn N. The role of HCV proteins on treatment outcomes. Virol J 2015;12:217. [PMID: 26666318 DOI: 10.1186/s12985-015-0450-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
155 Jardim AC, Bittar C, Matos RP, Yamasaki LH, Silva RA, Pinho JR, Fachini RM, Carareto CM, de Carvalho-Mello IM, Rahal P. Analysis of HCV quasispecies dynamic under selective pressure of combined therapy. BMC Infect Dis 2013;13:61. [PMID: 23374983 DOI: 10.1186/1471-2334-13-61] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
156 Onomoto K, Morimoto S, Kawaguchi T, Toyoda H, Tanaka M, Kuroda M, Uno K, Kumada T, Matsuda F, Shimotohno K, Fujita T, Murakami Y. Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. PLoS One 2011;6:e19799. [PMID: 21603632 DOI: 10.1371/journal.pone.0019799] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
157 El-Shamy A, Shoji I, Kim SR, Ide Y, Imoto S, Deng L, Yoon S, Fujisawa T, Tani S, Yano Y. Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy. PLoS One. 2012;7:e30513. [PMID: 22319571 DOI: 10.1371/journal.pone.0030513] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
158 Chen CH, Yu ML. Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat. 2010;2010:140953. [PMID: 21152178 DOI: 10.1155/2010/140953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
159 Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol. 2001;75:8516-8523. [PMID: 11507197 DOI: 10.1128/jvi.75.18.8516-8523.2001] [Cited by in Crossref: 379] [Cited by in F6Publishing: 176] [Article Influence: 19.0] [Reference Citation Analysis]
160 Bhattacharya D, Ansari IH, Mehle A, Striker R. Fluorescence resonance energy transfer-based intracellular assay for the conformation of hepatitis C virus drug target NS5A. J Virol 2012;86:8277-86. [PMID: 22623794 DOI: 10.1128/JVI.00645-12] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
161 Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011;204:84-93. [PMID: 21628662 DOI: 10.1093/infdis/jir210] [Cited by in Crossref: 98] [Cited by in F6Publishing: 89] [Article Influence: 9.8] [Reference Citation Analysis]
162 Bukh J, Pietschmann T, Lohmann V, Krieger N, Faulk K, Engle RE, Govindarajan S, Shapiro M, St Claire M, Bartenschlager R. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci USA. 2002;99:14416-14421. [PMID: 12391335 DOI: 10.1073/pnas.212532699] [Cited by in Crossref: 201] [Cited by in F6Publishing: 184] [Article Influence: 10.6] [Reference Citation Analysis]
163 Preciado MV, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L, Vazquez-Chacon C, Martinez-Guarneros A, Carpio-Pedroza JC, Fonseca-Coronado S, Cruz-Rivera M. Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. World J Gastroenterol 2014; 20(43): 15992-16013 [PMID: 25473152 DOI: 10.3748/wjg.v20.i43.15992] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
164 Tang Z, Köck J, Moradpour D, Yang D, Hao L, Blum H. [Implication of mutation of hepatitis C virus 1b interferon sensitivity determining region(NS5A aa 2209-2248) response to interferon alpha therapy in patients with chronic hepatitis C]. J Tongji Med Univ 1999;19:115-9. [PMID: 12840853 DOI: 10.1007/BF02886890] [Reference Citation Analysis]
165 Thomson EC, Smith JA, Klenerman P. The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals. J Gen Virol. 2011;92:2227-2236. [PMID: 21775583 DOI: 10.1099/vir.0.033910-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
166 Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002;76:2997-3006. [PMID: 11861865 DOI: 10.1128/jvi.76.6.2997-3006.2002] [Cited by in Crossref: 311] [Cited by in F6Publishing: 149] [Article Influence: 16.4] [Reference Citation Analysis]
167 Pavio N, Lai MM. The hepatitis C virus persistence: how to evade the immune system? J Biosci. 2003;28:287-304. [PMID: 12734407 DOI: 10.1007/bf02970148] [Cited by in Crossref: 64] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
168 Demetriou VL, Kyriakou E, Kostrikis LG. Near-full genome characterisation of two natural intergenotypic 2k/1b recombinant hepatitis C virus isolates. Adv Virol 2011;2011:710438. [PMID: 22315602 DOI: 10.1155/2011/710438] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
169 Lohmann V, Körner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol. 2001;75:1437-1449. [PMID: 11152517 DOI: 10.1128/jvi.75.3.1437-1449.2001.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
170 Sentandreu V, Jiménez-Hernández N, Torres-Puente M, Bracho MA, Valero A, Gosalbes MJ, Ortega E, Moya A, González-Candelas F. Evidence of recombination in intrapatient populations of hepatitis C virus. PLoS One. 2008;3:e3239. [PMID: 18800167 DOI: 10.1371/journal.pone.0003239] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
171 Roberts LO, Jopling CL, Jackson RJ, Willis AE. Viral strategies to subvert the mammalian translation machinery. Prog Mol Biol Transl Sci 2009;90:313-67. [PMID: 20374746 DOI: 10.1016/S1877-1173(09)90009-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
172 Tsutsumi T, Okushin K, Enooku K, Fujinaga H, Moriya K, Yotsuyanagi H, Aizaki H, Suzuki T, Matsuura Y, Koike K. Nonstructural 5A Protein of Hepatitis C Virus Interferes with Toll-Like Receptor Signaling and Suppresses the Interferon Response in Mouse Liver. PLoS One 2017;12:e0170461. [PMID: 28107512 DOI: 10.1371/journal.pone.0170461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M. Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1. J Clin Microbiol. 2013;51:2862-2868. [PMID: 23784126 DOI: 10.1128/jcm.01129-13] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
174 El-Shamy A, Hotta H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview. World J Gastroenterol 2014; 20(24): 7555-7569 [PMID: 24976696 DOI: 10.3748/wjg.v20.i24.7555] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
175 Antonelli G, Scagnolari C, Moschella F, Proietti E. Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use. Cytokine Growth Factor Rev 2015;26:121-31. [PMID: 25578520 DOI: 10.1016/j.cytogfr.2014.12.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
176 Perales C, Beach NM, Gallego I, Soria ME, Quer J, Esteban JI, Rice C, Domingo E, Sheldon J. Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. J Virol. 2013;87:7593-7607. [PMID: 23637397 DOI: 10.1128/jvi.02824-12] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
177 Tsuge M, Fujimoto Y, Hiraga N, Zhang Y, Ohnishi M, Kohno T, Abe H, Miki D, Imamura M, Takahashi S. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse. PLoS One. 2011;6:e23856. [PMID: 21886832 DOI: 10.1371/journal.pone.0023856] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
178 Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev. 2007;20:23-38. [PMID: 17223621 DOI: 10.1128/cmr.00010-06] [Cited by in Crossref: 106] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]
179 Karchava M, Waldenström J, Parker M, Hallack R, Sharvadze L, Gatserelia L, Chkhartishvili N, Dvali N, Dzigua L, Dolmazashvili E, Norder H, Tsertsvadze T. High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment. Hepatol Res 2015;45:1292-8. [PMID: 25689487 DOI: 10.1111/hepr.12505] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
180 Pietschmann T, Lohmann V, Kaul A, Krieger N, Rinck G, Rutter G, Strand D, Bartenschlager R. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol. 2002;76:4008-4021. [PMID: 11907240 DOI: 10.1128/jvi.76.8.4008-4021.2002] [Cited by in Crossref: 278] [Cited by in F6Publishing: 139] [Article Influence: 14.6] [Reference Citation Analysis]
181 Yuan HJ, Jain M, Snow KK, Gale M, Lee WM. Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*. J Viral Hepat. 2010;17:208-216. [PMID: 19656286 DOI: 10.1111/j.1365-2893.2009.01169.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
182 Krekulová L, Rehák V, Riley LW. Structure and functions of hepatitis C virus proteins: 15 years after. Folia Microbiol (Praha) 2006;51:665-80. [PMID: 17455808 DOI: 10.1007/BF02931636] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
183 García MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, Esteban M. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev. 2006;70:1032-1060. [PMID: 17158706 DOI: 10.1128/mmbr.00027-06] [Cited by in Crossref: 528] [Cited by in F6Publishing: 350] [Article Influence: 37.7] [Reference Citation Analysis]
184 Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010;30:1259-1269. [PMID: 20633102 DOI: 10.1111/j.1478-3231.2010.02283.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 11.2] [Reference Citation Analysis]
185 Lohmann V, Körner F, Dobierzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001;75:1437-49. [PMID: 11152517 DOI: 10.1128/JVI.75.3.1437-1449.2001] [Cited by in Crossref: 362] [Cited by in F6Publishing: 174] [Article Influence: 18.1] [Reference Citation Analysis]
186 Sugiyama R, Murayama A, Nitta S, Yamada N, Tasaka-Fujita M, Masaki T, Aly HH, Shiina M, Ryo A, Ishii K, Wakita T, Kato T. Interferon sensitivity-determining region of hepatitis C virus influences virus production and interferon signaling. Oncotarget 2018;9:5627-40. [PMID: 29464023 DOI: 10.18632/oncotarget.23562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
187 Maggi F, Vatteroni ML, Fornai C, Morrica A, Giorgi M, Bendinelli M, Pistello M. Subtype 2c of hepatitis C virus is highly prevalent in Italy and is heterogeneous in the NS5A region. J Clin Microbiol 1997;35:161-4. [PMID: 8968899 DOI: 10.1128/jcm.35.1.161-164.1997] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
188 Nasu A, Marusawa H, Ueda Y, Nishijima N, Takahashi K, Osaki Y, Yamashita Y, Inokuma T, Tamada T, Fujiwara T, Sato F, Shimizu K, Chiba T. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One 2011;6:e24907. [PMID: 21966381 DOI: 10.1371/journal.pone.0024907] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 7.0] [Reference Citation Analysis]
189 Fukuda R, Ishimura N, Ishihara S, Tokuda A, Satoh S, Sakai S, Akagi S, Watanabe M, Fukumoto S. Expression of interferon-alpha receptor mRNA in the liver in chronic liver diseases associated with hepatitis C virus: relation to effectiveness of interferon therapy. J Gastroenterol 1996;31:806-11. [PMID: 9027643 DOI: 10.1007/BF02358606] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
190 Jiang X, Kanda T, Wu S, Nakamoto S, Wakita T, Shirasawa H, Yokosuka O. Hepatitis C virus nonstructural protein 5A inhibits thapsigargin-induced apoptosis. PLoS One. 2014;9:e113499. [PMID: 25409163 DOI: 10.1371/journal.pone.0113499] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
191 Lusida MI, Nagano-Fujii M, Nidom CA, Soetjipto, Handajani R, Fujita T, Oka K, Hotta H. Correlation between mutations in the interferon sensitivity-determining region of NS5A protein and viral load of hepatitis C virus subtypes 1b, 1c, and 2a. J Clin Microbiol 2001;39:3858-64. [PMID: 11682498 DOI: 10.1128/JCM.39.11.3858-3864.2001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
192 Webby R, Hoffmann E, Webster R. Molecular constraints to interspecies transmission of viral pathogens. Nat Med 2004;10:S77-81. [PMID: 15577935 DOI: 10.1038/nm1151] [Cited by in Crossref: 78] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
193 Pascu M, Martus P, Höhne M, Wiedenmann B, Hopf U, Schreier E, Berg T. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut. 2004;53:1345-1351. [PMID: 15306598 DOI: 10.1136/gut.2003.031336] [Cited by in Crossref: 106] [Cited by in F6Publishing: 98] [Article Influence: 6.2] [Reference Citation Analysis]
194 Ogata S, Nagano-Fujii M, Ku Y, Yoon S, Hotta H. Comparative sequence analysis of the core protein and its frameshift product, the F protein, of hepatitis C virus subtype 1b strains obtained from patients with and without hepatocellular carcinoma. J Clin Microbiol. 2002;40:3625-3630. [PMID: 12354856 DOI: 10.1128/jcm.40.10.3625-3630.2002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
195 Toyoda H, Kumada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Arakawa T, Fujimori M, Niinomi T, Ando N, Yasuda S, Sakai K, Kimura J. High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b. J Gastroenterol 2011;46:501-9. [PMID: 20927636 DOI: 10.1007/s00535-010-0328-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
196 Murakami Y, Tanaka M, Toyoda H, Hayashi K, Kuroda M, Tajima A, Shimotohno K. Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics. 2010;3:48. [PMID: 20969775 DOI: 10.1186/1755-8794-3-48] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
197 Tan SL, Nakao H, He Y, Vijaysri S, Neddermann P, Jacobs BL, Mayer BJ, Katze MG. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA. 1999;96:5533-5538. [PMID: 10318918 DOI: 10.1073/pnas.96.10.5533] [Cited by in Crossref: 171] [Cited by in F6Publishing: 164] [Article Influence: 7.8] [Reference Citation Analysis]
198 Goyal A, Hofmann WP, Hermann E, Traver S, Hissar SS, Arora N, Blum HE, Zeuzem S, Sarrazin C, Sarin SK. The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India. Med Microbiol Immunol 2007;196:11-21. [PMID: 16955308 DOI: 10.1007/s00430-006-0024-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
199 Xu Z, Fan X, Xu Y, Di Bisceglie AM. Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a. J Virol 2008;82:9417-24. [PMID: 18667493 DOI: 10.1128/JVI.00896-08] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
200 Dimitrova M, Imbert I, Kieny MP, Schuster C. Protein-protein interactions between hepatitis C virus nonstructural proteins. J Virol. 2003;77:5401-5414. [PMID: 12692242 DOI: 10.1128/jvi.77.9.5401-5414.2003] [Cited by in Crossref: 140] [Cited by in F6Publishing: 83] [Article Influence: 7.8] [Reference Citation Analysis]
201 Shimakami T, Hijikata M, Luo H, Ma YY, Kaneko S, Shimotohno K, Murakami S. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. J Virol. 2004;78:2738-2748. [PMID: 14990694 DOI: 10.1128/JVI.78.6.2738-2748.2004] [Cited by in Crossref: 70] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
202 Goto K, Roca Suarez AA, Wrensch F, Baumert TF, Lupberger J. Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. Int J Mol Sci. 2020;21. [PMID: 32357520 DOI: 10.3390/ijms21093057] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]